The News Review:
- Global health science: a threat and an opportunity for collaborative…
- Clinical trials pose set of risks as well as institutional rewards;…
- Nextrials and ProTrials Collaborate to Accelerate Adoption of e…
Global health science: a threat and an opportunity for collaborative…
Nature.com – Nature.com (subscription) – Oct 22, 2007
I believe that investment in basic science is absolutely fundamental to ensure that we meet the greater challenges we will undoubtedly face in the future. The danger is that in the understandable excitement of the genomic revolution we have left the patient behind. Practice-orientated clinical research has not been given the funding it requires and even worse we have managed to make it so cumbersome complicated and bureaucractic that it has become easier to forget the patient and to focus solely on their genes or immune response6. This will come back to haunt us in the future when we will need to put all the major laboratory-based advances in the context of a human being. There is a very real danger that by the time we need these skills we will have lost those people with such ‘holistic’ skills. In seminal research from Kenya subsequently repeated in other settings clinical scientists have defined how important and common bacterial septicemia is in the context of ‘severe malaria’7. This work is of fundamental importance in terms of making patients better but it also underpins how crucial patient-orientated clinical research is to our understanding of laboratory science… By failing to define what is wrong with the patient with sufficient precison we will fail to make the most of the genomic revolution. This imbalance must be addressed. This means greater support for integrated clinical research that breaks down the artifical barriers between clinicians and scientists and encourages a holistic approach to clinical science and the patient6. We must address the issue of bureaucracy and over-regulation (neither of which has ever been the subject of any scientific assessment in terms of the benefits of the process versus risks in preventing crucial research) before it stops all clinical research8. This is particularly true for diseases of the developing world and for rapidly emerging disease threats that the pharmaceutical industry (which has the resources to afford to pay for the administrative and bureaucractic costs) on the whole are not interested in. It means that even basic patient-orientated clinical research in resource-poor settings can be done only when there is a rich partner to support the often unnecessary bureaucractic hurdles that commonly do little to ensure that the fundmentally important issues of good clinical practice good patient care and respect for the patient are in place. A new global agreement is needed on clinical research guidelines based on evidence and an appreciation of just how dangerous over-regulation can be to human health.
Clinical trials pose set of risks as well as institutional rewards;…
Free with registration – Business Insurance – AccessMyLibrary.com – Oct 22, 2007
Clinical trials pose set of risks as well as institutional rewards; Risk managers advised to take an active role in oversight. (22-CT-07) Business Insurance.
Nextrials and ProTrials Collaborate to Accelerate Adoption of e…
Free with registration – Business Wire – AccessMyLibrary.com – Oct 22, 2007
–>CPYRIGHT 2007 Business Wire Companies Form Strategic Alliance to ffer Advanced Clinical Trial Site Data and Services Management to Pharmaceutical Researchers with Fast-Tracked Product Pipelines SAN RAMN & MUNTAIN VIEW Calif. a leader in clinical research software and services and ProTrials Inc. a specialized contract research organization (CR) today announced an alliance aimed at accelerating study starts by supporting the use of electronic data capture (EDC) strategies within clinical trials. Together the companies make.
